BridgeBio Oncology Therapeutics Inc.
BBOT
Rank in Stocks
#17013
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Share Price
$2.30
Last synced: 2026-11-09
Market Cap
$184.40M
Change (1 day)
12.75%
Change (1 year)
-81.79%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade BridgeBio Oncology Therapeutics Inc. (BBOT)
Category
Healthcare
EPS for BridgeBio Oncology Therapeutics Inc. (BBOT)
EPS as of June 2026 TTM: $-1.23K
According to BridgeBio Oncology Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-1.23K. At the end of 2025 the company had an EPS of $-4.30, an increase over its 2024 EPS of $-5.76K.
EPS history for BridgeBio Oncology Therapeutics Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.23K | 28,570.23% |
| 2025 | $-4.30 | -99.93% |
| 2024 | $-5.76K | 287,820,400.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | -100.00% |
| 2021 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -101.27% |
US
|
|
| $-7.07 | -99.43% |
US
|
|
| $-5.29 | -99.57% |
AU
|
|
| $12.88 | -101.04% |
BE
|
|
| $21.56 | -101.75% |
NL
|
Questions about BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS)
What is BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS)?
BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-1.23K, as of Jun 2026.
What was BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) was $-4.30, compared with $-5.76K in 2024.
How has BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2024 ($-5.76K).
How does BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
BridgeBio Oncology Therapeutics Inc.'s earnings per share (EPS) ($-1.23K) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.